EAM Investors’s 4D Molecular Therapeutics FDMT Stock Holding History

EAM Investors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-96,225	Closed	-$3.07M	–	281
2024 Q1	$3.07M	Buy	+96,225	New	+$2.45M	0.48%	117

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's FDMT Position: Q2 2024 in Review

EAM Investors sold out of 4D Molecular Therapeutics (FDMT) in Q2 2024, closing a stake of 96,225 shares — an estimated $3.07M sold.

EAM Investors first reported a position in FDMT in Q1 2024 and held it in 1 quarter. The position peaked at $3.07M in Q1 2024. 143 funds tracked by Wall St. Rank hold FDMT as of Q2 2024.

EAM Investors reported no remaining 4D Molecular Therapeutics position as of Q2 2024 after selling out during the quarter.
EAM Investors sold 96,225 4D Molecular Therapeutics shares in Q2 2024, an estimated $3.07M.
EAM Investors first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 1 quarter.
EAM Investors's 4D Molecular Therapeutics position peaked at $3.07M in Q1 2024.
143 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.